We all know that immunotherapy has the potential for impressive response in the small minority of patients with mismatch repair deficient rectal cancer. Can immunotherapy improve outcomes among the much larger population with MMR proficient disease? TORCH was a randomized phase 2 trial designed to compare two different sequences of total neoadjuvant therapy (TNT) (both including immunotherapy) in order choose the better regimen to potentially pit against standard TNT in a phase 3 comparison. It was conducted at 6 Chinese centers and included 121 patients with pMMR, locally advanced rectal cancer. Most had stage III disease (90%) that was within 5cm of the anal verge (80%). In both arms patients received short course RT (25 Gy in 5 fractions) and 6 cycles of CAPOX plus the PD-1 inhibitor, toripalimab. The only difference between arms was the sequencing of RT. In the first, patients received RT first followed by 6 cycles of systemic therapy. In the second, they received 2 cycles of systemic therapy, RT, and the remaining 4 cycles. Restaging was performed at 4 weeks and the clinical CR rate was higher for those in the RT-first arm (43.5% v 35.6%). All patients with a cCR were offered a watch-and-wait strategy. Of the 32 who pursued WW, 94% were disease free at last follow up. Among patients who proceeded to surgery, the pCR rate was 50% in both arms. The overall CR rate (including both cCR and pCR) was similar between arms (56.5% v 54.2%). Though a smaller phase 2 study, the response rates seen in TORCH compare favorably with those of other TNT trials without immunotherapy such as RAPIDO (26%). | Xia, J Clin Oncol 2024

